Kyntra Bio (KYNB) Total Non-Current Liabilities (2014 - 2026)

Kyntra Bio has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $109.2 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 69.59% year-over-year to $109.2 million; the TTM figure through Jun 2026 stood at $109.2 million (down 69.59% YoY), while the FY2025 annual figure was $115.0 million, down 71.05% from the prior year.
• Total Non-Current Liabilities came in at $109.2 million for Q2 2026 at Kyntra Bio, down from $118.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $605.1 million in Q4 2022 to a low of $109.2 million in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $421.2 million, with a median of $513.1 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities jumped 51.55% in 2022 and plunged 74.33% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $605.1 million in 2022, then retreated by 3.68% to $582.9 million in 2023, then tumbled by 31.83% to $397.3 million in 2024, then tumbled by 71.05% to $115.0 million in 2025, then dropped by 5.11% to $109.2 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $109.2 million in Q2 2026, $118.8 million in Q1 2026, and $115.0 million in Q4 2025.